Merck Expands Pipeline into Eye Treatments

As reported by The Wall Street Journal, the pharma giant Merck, has acquired Inspire Pharmaceuticals in a deal worth $430million. The move highlights a strategic decision by the company to expand it’s pipeline into treatments for eye diseases.

Inspire Pharmaceuticals are the manufacturer of the eye treatments Azasite, which is used to target pinkeye caused by bacteria and Restasis which is used for dry-eye.

Are you looking for a new job in pharmaceuticals? Click here to search and apply for our latest pharmaceutical job opportunities.

Posted in: Industry News
CK Logo in place of featured image